Abiopharma

🔍 DIORIO CHRIS PH.D. (Executive)

Company: IMPINJ INC (PI)

Report Date: 2026-08-20

Detailed Transactions and Holdings:

• Acquired 3,753 shares of Common Stock (Direct)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 365,898.00 | transaction_form_type: 4
• Sold 1,477 shares of Common Stock at $159.73 per share (Direct)
  Date: 2026-08-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 364,421.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-20 | Code: H | nature_of_ownership: by DFT L.L.C. | shares_owned_after: 199,362.00
• Sold 3,753 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,262.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: In an exempt disposition to the Issuer under Rule 16b-3(e), the Reporting Person remitted shares to the Issuer in connection with the satisfaction of tax withholding obligations arising out of the vesting of restricted stock units, or RSUs.
• F2: Each RSU represents a contingent right to receive one share of Impinj common stock.
• F3: On August 20, 2025, the reporting person was granted 15,015 RSUs. One-fourth of these vested on August 20, 2026.